AI Article Synopsis
- The cardiorenal anemia syndrome in congestive heart failure (CHF) increases the risk of blood vessel-related health issues and mortality.
- Several factors contribute to anemia in CHF patients, including inflammation, kidney problems, the effects of specific medications, and loss of essential nutrients.
- While some trials indicate that erythropoietin (EPO) treatments could help CHF patients, further research is necessary to determine the best hemoglobin levels for effective treatment.
Article Abstract
The cardiorenal anemia syndrome in congestive heart failure (CHF) is an independent risk factor for vascular morbidity and mortality. Several factors play a role in the pathogenesis of anemia in CHF, including inflammation, impaired renal function, use of certain antihypertensive or cardioprotective agents, and gastrointestinal or urinary losses of essential hemopoietic factors. Several trials evaluated the effects of administering erythropoietin (EPO) and/or iron to patients with CHF. Even though most of them were uncontrolled studies, their results suggest that EPO treatment might be beneficial in CHF. Nevertheless, more studies are needed and certain issues should be resolved, particularly the optimal hemoglobin level, before EPO can become part of the treatment of patients with CHF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/0003319708316169 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!